Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SETD7 | Q8WTS6 | 2/20 | 0.48 |
| ▸ | SPR | P35270 | 5/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.39 |
| ▸ | GHSR | Q92847 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19474650 | 1.00 | SETD7 (0.48) | SETD7SPRGPR119MAP4K4POLB | |
| SCHEMBL19503514 | 1.00 | SETD7 (0.48) | SETD7SPRGPR119MAP4K4POLB | |
| SCHEMBL3294698 | 0.83 | POLB (0.55) | GPR119POLBMEN1MAPTTSHR | |
| SCHEMBL20913506 | 0.82 | SETD7 (0.55) | SETD7SPRGPR119MAP4K4POLB | |
| SCHEMBL20913505 | 0.82 | SETD7 (0.55) | SETD7SPRGPR119MAP4K4POLB | |
| SCHEMBL23560874 | 0.80 | MAP4K4 (0.54) | SETD7GPR119MAP4K4HDAC1 | |
| SCHEMBL4684385 | 0.76 | SETD7 (0.49) | SETD7SPRGPR119MAP4K4HDAC1 | |
| SCHEMBL4681133 | 0.76 | SETD7 (0.49) | SETD7SPRGPR119MAP4K4HDAC1 | |
| SCHEMBL21884859 | 0.76 | SETD7 (0.49) | SETD7SPRGPR119MAP4K4HDAC1 | |
| SCHEMBL4336794 | 0.75 | SETD7 (0.52) | SETD7SPRMAP4K4MEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10781205-B2 | Conjugates comprising RIPK2 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-09-22 | — | — | US | disclosed |
| US-20190119271-A1 | CONJUGATES COMPRISING RIPK2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10781205-B2 | Conjugates comprising RIPK2 inhibitors | RIPK2, RIPK1, RIPK4 | SETD7 2808/4885SPR 3259/4885GPR119 2257/4885 |
| US-20190119271-A1 | CONJUGATES COMPRISING RIPK2 INHIBITORS | RIPK2, RIPK1, RIPK4 | SETD7 2808/4885SPR 3259/4885GPR119 2257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.